Previous 10 | Next 10 |
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today announced changes to its senior management team to focus the company...
Ovid Therapeutics (NASDAQ: OVID ): Q4 GAAP EPS of -$0.52. More news on: Ovid Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological disorders, today reported financial results for the fourth quarter and full year ended ...
NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that Jeremy Levin, DPhil, MB BChir, Chairman and Chief E...
Gainers: Kandi Technologies Group (NASDAQ: KNDI ) +47% . LeMaitre Vascular (NASDAQ: LMAT ) +28% . AzurRx BioPharma (NASDAQ: AZRX ) +29% . Blink Charging (NASDAQ: BLNK ) +21% . Carrols Restaurant Group (NASDAQ: TAST ) +17% . OneSpan (NASDAQ: OSPN ) +17% . Garmin (NASDAQ: GRMN ) ...
NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced the pricing of underwritten public offerings of (i) 12,50...
NEW YORK, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it intends to offer and sell shares of its common stock a...
The following slide deck was published by Ovid Therapeutics Inc. in conjunction with this Read more ...
Dr. Werber will join Cowen and Company as Managing Director and Senior Biotechnology Analyst effective September 24, 2018 Ovid has initiated a search to select a new CFO NEW YORK, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company comm...
NEW YORK, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that the company will present at two upcoming investor conferen...
News, Short Squeeze, Breakout and More Instantly...
Ovid Therapeutics Inc. Company Name:
OVID Stock Symbol:
NASDAQ Market:
Ovid Therapeutics Inc. Website:
Neurologists/epileptologists Dr. Imad Najm of the Cleveland Clinic Neurological Institute and the Cleveland Clinic Epilepsy Center, and Dr. Raman Sankar, the Emeritus Chief of Pediatric Neurology at UCLA Health, appointed to Ovid’s Scientific Advisory Board (SAB) Neuroscientists Dr. Ja...
Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and pr...
The Phase 1 study for OV888/GV101 capsule met its objective, demonstrating a favorable safety and tolerability profile with no serious adverse events Secondary endpoint results indicate that the target pharmacokinetic profile was achieved at the targeted clinical dose, supporting once daily d...